By simultaneously inhibiting both PD-L1 and TGF-β signalings, SHR-1701 has exhibited potential enhanced anti-tumor immunity in preliminary clinical studies of advanced solid tumors, such as cervical and gastric cancers, compared to PD1/PD-L1 monotherapies.16–21. Here, CD274 is linked to neoplasm.